Analysis of the Predictive Value of CA125 Elimination Rate Constant (KELIM) for Outcomes of Interval Debulking Surgery and Prognosis in High-Grade Serous Ovarian Cancer

Chaorong Zeng; Zhuoying Hu*

Chaorong Zeng and Zhuoying Hu*

Volume6-Issue2
Dates: Received: 2024-11-24 | Accepted: 2025-02-14 | Published: 2025-02-15
Pages: 139-152

Abstract

Objective: To determine the cutoff value of the KELIM score in patients with High-Grade Serous Ovarian Cancer (HGSOC) undergoing Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS), and to better assess the significance of the KELIM score as a prognostic and predictive indicator for HGSOC.

Methods: A total of 124 patients with HGSOC who underwent NACT+IDS were included. The Receiver Operating Characteristic (ROC) curve and Youden index were used to determine the cutoff value of the KELIM score for predicting complete cytoreductive surgery (R0 resection) in HGSOC patients undergoing NACT. Logistic regression analysis was conducted to identify factors predicting complete cytoreductive surgery, and Cox regression analysis was used to assess the correlation between the KELIM score and recurrence and mortality in HGSOC. Based on the cutoff value of the KELIM score, patients were divided into two groups, and differences in clinic pathological parameters between the groups were compared.

Results: The optimal cutoff value of the KELIM score for predicting R0 resection was 1.25. The KELIM score was identified as an independent risk factor for both R0 resection and recurrence in patients with HGSOC.

Conclusion: A KELIM score cutoff of 1.25 is optimal for predicting complete cytoreductive surgery and recurrence in patients with high-grade serous ovarian cancer.

FullText HTML FullText PDF DOI: 10.37871/jbres2066

Certificate of Publication

Copyright

How to cite this article

Zeng C, Hu Z. Analysis of the Predictive Value of CA125 Elimination Rate Constant (KELIM) for Outcomes of Interval Debulking Surgery and Prognosis in High-Grade Serous Ovarian Cancer. J Biomed Res Environ Sci. 2025 Feb 15; 6(1): 139-152. doi: 10.37871/jbres2066, Article ID: JBRES2066, Available at: https://www. jelsciences.com/articles/jbres2066.pdf

Subject area(s)

Oncology

Gynecology

Cancer

References

Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K. Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer. Oncologist. 2016 Jun;21(6):745-54. doi: 10.1634/theoncologist.2015-0239. Epub 2016 Mar 23. PMID: 27009938; PMCID: PMC4912357.
Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015 Mar 10;33(8):937-43. doi: 10.1200/JCO.2014.56.3106. Epub 2015 Feb 9. PMID: 25667285; PMCID: PMC4348639.
Rutten MJ, van de Vrie R, Bruining A, Spijkerboer AM, Mol BW, Kenter GG, Buist MR. Predicting surgical outcome in patients with International Federation of Gynecology and Obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models. Int J Gynecol Cancer. 2015 Mar;25(3):407-15. doi: 10.1097/IGC.0000000000000368. PMID: 25695545.
van de Vrie R, Rutten MJ, Asseler JD, Leeflang MM, Kenter GG, Mol BWJ, Buist M. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. Cochrane Database Syst Rev. 2019 Mar 23;3(3):CD009786. doi: 10.1002/14651858.CD009786.pub3. PMID: 30907434; PMCID: PMC6432174.
You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013. Epub 2013 May 18. PMID: 23694718.
Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B. Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. Br J Cancer. 2014 Mar 18;110(6):1517-24. doi: 10.1038/bjc.2014.75. Epub 2014 Feb 20. PMID: 24556626; PMCID: PMC3960627.
You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, Tod M, Wilbaux M, Freyer G, Seckl MJ. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer. 2013 May 14;108(9):1810-6. doi: 10.1038/bjc.2013.123. Epub 2013 Apr 16. PMID: 23591194; PMCID: PMC3664307.
Wilbaux M, Hénin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, Tod M, You B. Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecol Oncol. 2014 Jun;133(3):460-6. doi: 10.1016/j.ygyno.2014.04.003. Epub 2014 Apr 12. PMID: 24726614.
You B, Colomban O, Tod M, Ray Coquard I, Lortholary A, Hardy-Bessard AC, Du Bois A, Huober J, Meier W, Kurzeder C, Pfisterer J. The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets Annals of Oncology. 2016;27(6):296-312. doi:10.1093/annonc/mdw374.4.
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24. PMID: 32209570.
Colomban O, Clamp A, Cook A, McNeish IA, You B. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO Clin Cancer Inform. 2023 Apr;7:e2200188. doi: 10.1200/CCI.22.00188. PMID: 37075255; PMCID: PMC10281428.
You B, Van Wagensveld L, Tod M, Gabe SS, Roy K, Du Bois A, Selle F, Timothy P, Pfisterer J, Florence J, Cook A, Kaminsky-Forrett MC, Wollschlaeger K, Alain L, Oliver T, Alexandra L, Freyer G, Maaike van der Aa, Olivier C. The impact of chemosensitivity assessed by modeled CA-125 KELlM on the likelihood of long progression-free survivorship(PS)after 1st line treatment in ovarian cancer:an analysis of 4450 patients. Annals of Oncology. 2020;31:S616. doi: 10.1016/j.annonc.2020.08.954.
You B, Van Wagensveld L, Tod M, Sonke GS, Horlings HM, Kruitwagen RFPM, Du Bois A, Selle F, Perren T, Pfisterer J, Joly F, Cook A, Kaminsky MC, Wollschlaeger K, Lortholary A, Tome O, Leary A, Freyer G, Van Der Aa M, Colomban O. Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. Br J Cancer. 2022 Jul;127(1):79-83. doi: 10.1038/s41416-022-01732-7. Epub 2022 Mar 31. PMID: 35361918; PMCID: PMC9276767.
van Wagensveld L, Colomban O, van der Aa MA, Freyer G, Sonke GS, Kruitwagen RFPM, You B. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". J Gynecol Oncol. 2024 May;35(3):e34. doi: 10.3802/jgo.2024.35.e34. Epub 2024 Jan 8. PMID: 38216134; PMCID: PMC11107274.
Zouzoulas D, Tsolakidis D, Tzitzis P, Sofianou I, Chatzistamatiou K, Theodoulidis V, Topalidou M, Timotheadou E, Grimbizis G. The Use of CA-125 KELIM to Identify Which Patients Can Achieve Complete Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Serous Advanced Ovarian Cancer. Cancers (Basel). 2024 Mar 24;16(7):1266. doi: 10.3390/cancers16071266. PMID: 38610943; PMCID: PMC11010898.
Sepulveda ZV, Marin-jimenez JA, Ortiz l,et al. KELlM during neoadjuvant chemotherapy as predictor of interval debulking surgery and treatment response in advanced ovarian cancer. Int J Gynecol Cancer. 2023;33.
Piedimonte S, Kim R, Bernardini MQ, Atenafu EG, Clark M, Lheureux S, May T. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecol Oncol. 2022 Dec;167(3):417-422. doi: 10.1016/j.ygyno.2022.10.014. Epub 2022 Oct 27. PMID: 37191644.
Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020 Nov 9;371:m3773. doi: 10.1136/bmj.m3773. PMID: 33168565.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774.
Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E; participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011 May;21(4):750-5. doi: 10.1097/IGC.0b013e31821b2568. PMID: 21543936.
Vincent L, Jankowski C, Ouldamer L, Ballester M, Bendifallah S, Bolze PA, Akladios C, Costaz H, Lavoué V, Canlorbe G, Collinet P, Touboul C, Huchon C, Bricou A, Dridi S, Padéano MM, Bengrine L, Arnould L, Coutant C; Groupe de Recherche FRANCOGYN. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group. Eur J Surg Oncol. 2020 Sep;46(9):1689-1696. doi: 10.1016/j.ejso.2020.04.029. Epub 2020 Apr 24. PMID: 32417154.
Ducoulombier S, Golfier F, Colomban O, Benayoun D, Bolze PA, Tod M, You B. Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer. Anticancer Res. 2017 Dec;37(12):6879-6886. doi: 10.21873/anticanres.12150. PMID: 29187468.
Li C, Cui Q, Wang X, Yao S, Tu H, Chen M. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals. BMC Cancer. 2024 May 20;24(1):609. doi: 10.1186/s12885-024-12252-3. PMID: 38769484; PMCID: PMC11107035.
Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, Long Roche K, Tew WP. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. J Gynecol Oncol. 2020 Jan;31(1):e17. doi: 10.3802/jgo.2020.31.e17. PMID: 31833259; PMCID: PMC6918896.
Bouvarel B, Colomban O, Frenel JS, Loaec C, Bourgin C, Berton D, Freyer G, You B, Classe JM. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients. Int J Gynecol Cancer. 2024 Apr 1;34(4):574-580. doi: 10.1136/ijgc-2023-004872. PMID: 38242546.
Kim JH, Cho HW, Park EY, Han KH, Kim ET, Lee JK, Park SY, Armbrust R, Fotopoulou C, Lim MC. Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2023 Dec 4;33(12):1913-1920. doi: 10.1136/ijgc-2023-004825. PMID: 37949486.
Vallius T, Hynninen J, Auranen A, Carpén O, Matomäki J, Oksa S, Virtanen J, Grénman S. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol. 2014 Dec;35(12):12389-95. doi: 10.1007/s13277-014-2553-1. Epub 2014 Sep 5. PMID: 25190018.
Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis. Int J Gynecol Cancer. 2016 Nov;26(9):1586-1593. doi: 10.1097/IGC.0000000000000804. PMID: 27540691.
Chudecka-Głaz A, Cymbaluk-Płoska A, Wężowska M, Menkiszak J. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients? PLoS One. 2018 Mar 27;13(3):e0194270. doi: 10.1371/journal.pone.0194270. PMID: 29584739; PMCID: PMC5870956.
Colomban O, Tod M, Leary A, Ray-Coquard IL, Lortholary A, Hardy-Bessard AC, Pfisterer J, Du Bois A, Kurzeder C, Burges A,Peron J, Freyer G, You B. Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)[J]. Annals of Oncology. 2019;30(419). doi: 10.1093/annonc/mdz250.035.
Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13. PMID: 26463832; PMCID: PMC4631624.